News Headlines Article

Gilead stock drops on hepatitis C drug’s heart warning
San Francisco Business Times

Gilead Sciences Inc., which warned doctors and other health-care providers late last week not to use its groundbreaking hepatitis C drugs with patients on a well-known heart medication, saw its stock drop 2 percent in trading Monday. The Foster City-based drug developer (NASDAQ: GILD) said one patient taking its drugs Harvoni or Sovaldi as well as the heart drug amiodarone died of cardiac arrest and three required a pacemaker. In all, the company said, nine patients developed abnormally slow heartbeats.